Leveraging novel technologies
uniquely suited to the eye
ATSENA THERAPEUTICS’ next-generation adeno-associated virus (AAV) technologies – laterally spreading capsids, dual vectors, and intravitreal capsids – are designed to overcome the limitations of current gene therapies and address the significant unmet need in inherited retinal diseases.
Our technologies are uniquely suited for the prevention or reversal of blindness. We utilize an AAV capsid, payload and delivery approach that is engineered for each disease, and our AAV vectors are designed for delivery via subretinal or intravitreal injection.